DK2671954T3 - Translokation og mutant ROS-kinase i human ikke-småcellet lungekarcinom - Google Patents

Translokation og mutant ROS-kinase i human ikke-småcellet lungekarcinom Download PDF

Info

Publication number
DK2671954T3
DK2671954T3 DK13176525.7T DK13176525T DK2671954T3 DK 2671954 T3 DK2671954 T3 DK 2671954T3 DK 13176525 T DK13176525 T DK 13176525T DK 2671954 T3 DK2671954 T3 DK 2671954T3
Authority
DK
Denmark
Prior art keywords
ros
leu
slc34a2
ser
gly
Prior art date
Application number
DK13176525.7T
Other languages
English (en)
Inventor
Ailan Guo
Anthony Possemato
Original Assignee
Cell Signaling Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38288244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2671954(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Signaling Technology Inc filed Critical Cell Signaling Technology Inc
Application granted granted Critical
Publication of DK2671954T3 publication Critical patent/DK2671954T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)

Claims (16)

1. Fremgangsmåde til at karakterisere lungekræft omfattende at detektere tilstedeværelsen afen ROS-mutation i en biologisk prøve fra en human lungekræft.
2. Fremgangsmåden ifølge krav 1, hvor fremgangsmåden omfatter at detektere tilstedeværelsen af et SLC34A2-ROS-fusionspolynukleotid.
3. Fremgangsmåden ifølge krav 1, hvor lungekræften er en ikke-småcellet lungekræft (NSCLC).
4. Fremgangsmåden ifølge et hvilket som helst af kravene 2 til 3, hvor SLC34A2-ROS-fusionspolynukleotidet koder for et SLC34A2-ROS-fusionspolypeptid, hvilket omfatter en aminosyresekvens mindst 95 % identisk med SEQ ID NO: 1 eller 3.
5. Fremgangsmåden ifølge krav 4, hvor SLC34A2-ROS-fusionspolypeptidet omfatter aminosyresekvensen af SEQ ID NO: 1 eller 3.
6. Fremgangsmåden ifølge et hvilket som helst af kravene 2 til 3, hvor SLC34A2-ROS-fusionspolypeptidet omfatter en N-terminal aminosyresekvens af SLC34A2 der består af rester mindst 95 % identisk med rester 1-126 af SEQ ID NO: 5 og kinasedomænet af ROS der består af rester mindst 95 % identisk med rester 1945-2222of SEQ ID NO: 7.
7. Fremgangsmåden ifølge krav 6, hvor SLC34A2-ROS-fusionspolypeptidet omfatter en N-terminal aminosyresekvens af SLC34A2 der består af rester 1-126 af SEQ ID NO: 5 og kinasedomænet af ROS der består af aminosyrerester 1945-2222.
8. Fremgangsmåden ifølge krav 7, hvor kinasedomænet af ROS består af aminosyrerester 1750-2347 eller 1853-2347 af SEQ ID NO: 7.
9. Fremgangsmåden ifølge krav 2, hvor SLC34A2-ROS-fusionspolynukleotidet omfatter en N-terminal nukleotidsekvens af SLC34A2 der består af rester mindst 95 % identisk med rester 1-378 af SEQ ID NO:6 og en kinasedomæne-nukleotidsekvens mindst 95 % identisk med nukleotidsekvensen som fremsat i nukleotider 6032-6865 af SEQ ID NO: 8.
10. Fremgangsmåden ifølge krav 9, hvor SLC34A2-ROS-fusionspolynukleotidet omfatter en N-terminal nukleotidsekvens af SLC34A2 der består af rester 1-378 af SEQ ID NO:6 og en kinasedomæne-nukleotidsekvens som fremsat i nukleotider 6032-6865 af SEQ ID NO: 8.
11. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 3, hvor tilstedeværelsen af ROS-fusionspolynukleotidet detekteres under anvendelse af et polymerase-kædereaktions-(PCR)-assay.
12. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 3, hvor tilstedeværelsen af ROS-fusionspolynukleotidet detekteres under anvendelse af et in s/tu-hybridiserings-CISHj-assay.
13. Fremgangsmåden ifølge krav 12, hvor ISH-assayet udføres under anvendelse af breakapart genprober.
14. Fremgangsmåde til at detektere en ROS-genmutation i human lungekræft, omfattende: at detektere en ROS-genmutation i en biologisk prøve fra nævnte humane lungekræft, i et fluorescens in s/tu-hybridiserings-CFISHj-assay.
15. Fremgangsmåden ifølge krav 14, hvor nævnte assay udføres under anvendelse af breakapart prober, der hybridiserer til et vildtype-kromosom ved modstående sider af et brudpunkt på ROS-genet.
16. Fremgangsmåden ifølge krav 14 eller krav 15, hvor lungekræften er en ikke-småcellet lungekræft (NSCLC).
DK13176525.7T 2006-01-20 2007-01-19 Translokation og mutant ROS-kinase i human ikke-småcellet lungekarcinom DK2671954T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76063406P 2006-01-20 2006-01-20
EP07718104.8A EP1973946B1 (en) 2006-01-20 2007-01-19 Translocation and mutant ros kinase in human non-small cell lung carcinoma

Publications (1)

Publication Number Publication Date
DK2671954T3 true DK2671954T3 (da) 2018-08-13

Family

ID=38288244

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07718104.8T DK1973946T3 (da) 2006-01-20 2007-01-19 Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom
DK13176525.7T DK2671954T3 (da) 2006-01-20 2007-01-19 Translokation og mutant ROS-kinase i human ikke-småcellet lungekarcinom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07718104.8T DK1973946T3 (da) 2006-01-20 2007-01-19 Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom

Country Status (10)

Country Link
EP (4) EP2671954B1 (da)
JP (7) JP5554925B2 (da)
CN (2) CN103981198B (da)
DK (2) DK1973946T3 (da)
ES (2) ES2539830T3 (da)
HK (2) HK1120272A1 (da)
HU (1) HUE039085T2 (da)
PT (1) PT2671954T (da)
SI (1) SI2671954T1 (da)
WO (1) WO2007084631A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1973946T3 (da) * 2006-01-20 2015-06-22 Cell Signaling Technology Inc Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
EP2203558B1 (en) 2007-10-18 2016-05-04 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
HUE035769T2 (en) * 2009-02-12 2018-05-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
EP2586862B9 (en) 2010-06-22 2016-07-13 LSI Medience Corporation Detection method for novel ros1 fusion product
KR20140041906A (ko) 2011-08-02 2014-04-04 화이자 인코포레이티드 암의 치료에 사용하기 위한 크리조티닙
JP2015508644A (ja) * 2012-02-08 2015-03-23 インサイト ジェネティクス インコーポレイテッド 癌の診断および治療のためのｒｏｓ１の融合体に関する方法および組成物
WO2015075196A1 (en) * 2013-11-21 2015-05-28 Assistance Publique - Hopitaux De Paris Method for detecting chromosomal rearrangements
CN107236818A (zh) * 2017-07-19 2017-10-10 臻悦生物科技江苏有限公司 肺癌临床用药突变基因检测试剂盒
EP3665301B1 (en) * 2017-08-09 2023-10-04 PamGene B.V. Method for predicting the response of non-small-cell lung carcinoma patients to a medicament
CN108148912B (zh) * 2018-03-08 2021-10-08 四川大学 肿瘤的生物标志物、应用和肿瘤检测试剂盒
WO2020223133A1 (en) * 2019-04-30 2020-11-05 Encodia, Inc. Methods and reagents for cleavage of the n-terminal amino acid from a polypeptide
CN110655080B (zh) * 2019-10-25 2022-08-05 山东大学 一种具有选择性杀灭癌细胞功能的无氧化Ti3C2量子点及其制备方法与应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
CA1255586A (en) 1984-07-24 1989-06-13 Hendrik M. Geysen Method of determining mimotopes
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co MICROORGANISM PRODUCING TRYPTOPHANE.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
CA1339069C (en) 1987-11-09 1997-07-29 Henry Lee Niman Polypeptide-induced monoclonal receptors to protein ligand
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
CA2074720C (en) * 1990-01-26 2002-07-23 Martin A. Cheever Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy
EP1566442B1 (de) 1990-02-01 2009-11-25 Siemens Healthcare Diagnostics Products GmbH Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
DE59109269D1 (de) 1990-06-28 2005-12-15 Hoechst Ag Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
EP0654077A4 (en) 1992-07-17 1996-03-13 Ribozyme Pharm Inc PROCESS AND REAGENT FOR THE TREATMENT OF DISEASES IN ANIMALS.
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6323316B1 (en) * 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
JP2003528024A (ja) 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
US7198896B2 (en) 1998-09-04 2007-04-03 Cell Signaling Technology, Inc. Immunoaffinity isolation of modified peptides from complex mixtures
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US7662793B2 (en) 1999-06-18 2010-02-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
US6362324B1 (en) * 1999-06-30 2002-03-26 Millennium Pharmaceuticals, Inc. 17867 a novel human aminopeptidase
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
WO2002044321A2 (en) 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
PE20020801A1 (es) 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
CA2447612A1 (en) 2001-05-17 2002-11-28 The Public Health Research Institute Of The City Of New York, Inc. Selection of target sites for antisense attack of rna
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
EP1472539B1 (en) 2001-08-14 2011-05-04 President and Fellows of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US20030219839A1 (en) 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
AU2003239505A1 (en) 2002-05-20 2003-12-12 Amgen Fremont Inc. Treatment of renal carcinoma using antibodies against the egfr
EP1581554A2 (en) * 2002-07-04 2005-10-05 Nalan Utku Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
DK1675961T3 (da) * 2003-10-24 2009-02-23 Oncalis Ag Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer
US7424370B2 (en) * 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
DK1973946T3 (da) * 2006-01-20 2015-06-22 Cell Signaling Technology Inc Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom

Also Published As

Publication number Publication date
JP2023039988A (ja) 2023-03-22
JP2017070286A (ja) 2017-04-13
EP1973946A2 (en) 2008-10-01
EP3360965A1 (en) 2018-08-15
JP2019068816A (ja) 2019-05-09
EP1973946B1 (en) 2015-03-25
HK1120272A1 (en) 2009-03-27
EP1973946A4 (en) 2010-08-11
JP2019141060A (ja) 2019-08-29
JP5554925B2 (ja) 2014-07-23
EP3936621A1 (en) 2022-01-12
CN103981198B (zh) 2020-09-01
EP2671954B1 (en) 2018-05-16
JP6957546B2 (ja) 2021-11-02
ES2539830T3 (es) 2015-07-06
HUE039085T2 (hu) 2018-12-28
JP2014140371A (ja) 2014-08-07
HK1256305A1 (zh) 2019-09-20
ES2683846T3 (es) 2018-09-28
SI2671954T1 (sl) 2018-11-30
WO2007084631A2 (en) 2007-07-26
PT2671954T (pt) 2018-10-08
EP2671954A2 (en) 2013-12-11
CN101528921B (zh) 2013-11-20
JP6521928B2 (ja) 2019-05-29
CN101528921A (zh) 2009-09-09
DK1973946T3 (da) 2015-06-22
WO2007084631A3 (en) 2008-12-31
EP2671954A3 (en) 2014-02-12
JP7262214B2 (ja) 2023-04-21
JP2021006039A (ja) 2021-01-21
JP2009523446A (ja) 2009-06-25
JP6259320B2 (ja) 2018-01-10
CN103981198A (zh) 2014-08-13

Similar Documents

Publication Publication Date Title
JP7262214B2 (ja) ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
US11761005B2 (en) Translocation and mutant ROS kinase in human non-small cell lung carcinoma
AU2017203548B2 (en) Translocation and mutant ROS kinase in human non-small cell lung carcinoma
WO2007075933A2 (en) Translocation and mutant csf1r kinase in human leukemia
US20100143918A1 (en) Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20100266580A1 (en) Translocation and mutant tnk1 kinase in human lymphoma